Literature DB >> 15957720

A comparison of open and laparoscopic approaches to adrenalectomy in patients with phaeochromocytoma.

M J Davies1, D P McGlade, S W Banting.   

Abstract

We compared the perioperative profiles of patients undergoing unilateral phaeochromocytoma resection performed by open adrenalectomy with those performed by laparoscopic adrenalectomy. Data was collected prospectively on 24 patients (12 open, 12 laparoscopic). All patients underwent extensive preoperative medical preparation with phenoxybenzamine and beta-blockers. The final preoperative dose of phenoxybenzamine was similar in each group (laparoscopic 119+/-60 mg/day, open 100+/-25 mg/day). Intraoperative haemodynamic instability was assessed by the requirement for therapeutic intervention. More haemodynamic instability was observed in the laparoscopic group but the differences were not statistically significant. Sodium nitroprusside use to treat hypertension (systolic blood pressure >180 mmHg) was more frequent and the duration of the infusions longer in the laparoscopic group; high dose beta-blocker therapy with atenolol and/or esmolol to treat intraoperative tachycardia (heart rate >90) was also more frequent in the laparoscopic group. The small sample size of the study limited the ability to detect a true difference. Blood loss was greater in the open adrenalectomy group but the difference was not significant. The operating time was significantly longer (236+/-78 vs 147+/-47 min, P<0.01) but the duration of postoperative hospitalization was significantly shorter (5+/-2 vs 11+/-4 days, P<0.01) in the laparoscopic group. Postoperative complications were not significantly different. There were no perioperative deaths. Overall, we observed more haemodynamic instability in patients undergoing laparoscopic resection but were unable to demonstrate a statistically significant difference. In our experience, laparoscopic adrenalectomy has the advantage of a shorter time to discharge from hospital.

Entities:  

Mesh:

Year:  2004        PMID: 15957720     DOI: 10.1177/0310057X0403200210

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  6 in total

1.  SAGES guidelines for minimally invasive treatment of adrenal pathology.

Authors:  Dimitrios Stefanidis; Melanie Goldfarb; Kent W Kercher; William W Hope; William Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2013-09-10       Impact factor: 4.584

2.  Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?

Authors:  Amit Agarwal; Prateek K Mehrotra; Manoj Jain; Sushil K Gupta; Anjali Mishra; Gyan Chand; Gaurav Agarwal; A K Verma; S K Mishra; Uttam Singh
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

3.  Is laparoscopic left adrenalectomy with the anterior submesocolic approach for Conn's or Cushing's syndrome equally safe and effective as the lateral and anterior ones?

Authors:  Andrea Balla; Silvia Quaresima; Livia Palmieri; Monica Ortenzi; Emilia Sbardella; Giulia Puliani; Andrea M Isidori; Mario Guerrieri; Alessandro M Paganini
Journal:  Surg Endosc       Date:  2018-11-19       Impact factor: 4.584

4.  Laparoscopic adrenalectomy for large unilateral pheochromocytoma: experience in a large academic medical center.

Authors:  Kyle A Perry; Raphael El Youssef; Thai H Pham; Brett C Sheppard
Journal:  Surg Endosc       Date:  2009-12-24       Impact factor: 4.584

5.  Laparoscopic versus open surgery for pheochromocytoma: a meta-analysis.

Authors:  Sheng-Qiang Fu; Si-Yuan Wang; Qiang Chen; Yu-Tang Liu; Zhi-Long Li; Ting Sun
Journal:  BMC Surg       Date:  2020-07-25       Impact factor: 2.102

6.  Incidence, risk factors and clinical significance of postoperative haemodynamic instability after adrenalectomy for phaeochromocytoma.

Authors:  Joseph P Thompson; Davinia Bennett; James Hodson; Miriam Asia; John Ayuk; Michael W O'Reilly; Niki Karavitaki; Wiebke Arlt; Robert P Sutcliffe
Journal:  Gland Surg       Date:  2019-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.